NCT04264715

Brief Summary

Operating room S. aureus exposure has been directly linked to postoperative infections and is therefore an important target for infection prevention. Visible light (non-ultraviolet spectrum) at 405nm has been shown to be germicidal. We hypothesize that use of this light in operating rooms will reduce S. aureus transmission occurring within and between patients and reduce surgical site infections (SSIs). Visible light is safe for routine, continual exposure, and is less harmful than sunlight. We plan to install ambient, germicidal lighting in 4 operating rooms. This ambient light is not directly applied to patients (does not involve the surgical procedure lights). Patients will undergo surgery according to usual practice. We will conduct a case-control study where operating rooms with surgeries with the lights are matched to operating rooms with surgeries without lights. In Aim 1, 4 OR-pairs will be observed each day over an anticipated 103 working days for the primary outcome of S. aureus transmission events over a total minimum study period of 5.2 months (103 working days).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
824

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 6, 2020

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

February 9, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 11, 2020

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

February 12, 2020

Status Verified

February 1, 2020

Enrollment Period

12 months

First QC Date

February 9, 2020

Last Update Submit

February 11, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Staphylococcus aureus transmission rate

    We will be assessing the transmission of bacteria to the patient during the case and from previous cases to subsequent cases.

    sequential surgeries on the same 1 day

Study Arms (2)

405nm light room

EXPERIMENTAL

In this room, surgeries will be performed under ambient light including the wavelength 405nm

Device: 405nm light

Control room

NO INTERVENTION

In this room, surgeries will be performed under ambient light from regular phosphorescent light does not include 405nm frequencies

Interventions

In this room, surgeries will be performed under ambient light including the wavelength 405nm

405nm light room

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Operating Rooms with and without the bactericidal lights where adult patients undergoing orthopedic, cardiothoracic, gynecology/oncology, and neurological surgery.

You may not qualify if:

  • Operating Rooms with and without the bactericidal lights where pediatric, incarcerated, and/or pregnant patients undergoing surgery outside of the classifications above.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Northwestern Lake Forest Hospital

Lake Forest, Illinois, 60045, United States

RECRUITING

MeSH Terms

Interventions

Ultraviolet Therapy

Intervention Hierarchy (Ancestors)

PhototherapyTherapeutics

Central Study Contacts

Andrew Gostine, MD, MBA

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Anesthesiologist and Intensivist

Study Record Dates

First Submitted

February 9, 2020

First Posted

February 11, 2020

Study Start

January 6, 2020

Primary Completion

December 31, 2020

Study Completion

December 31, 2020

Last Updated

February 12, 2020

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share

Locations